Skip to main content

From the helm: Proteomics International (ASX:PIQ), Dr. Richard Lipscombe, Managing Director

Bell Direct
July 7, 2025

In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.

In this video, Dr. Lipscombe covers:
·      (0:47): An overview of PIQ and its FY26 goals
·      (1:38): The significance of three world-first blood tests
·      (5:26): The global addressable markets for these conditions
·      (6:25): Clinical trial progress and commercialisation roadmap
·      (8:14): How the diagnostic tests work and deliver value to patients
·      (9:16): Commercialisation strategy across key regions
·      (11:23): Additional assets in the PIQ pipeline
·      (12:36): What investors can expect over the next 12 months

Note: This interview was recorded on 3 July 2025.

Morning Bell 22 January

Bell Direct
January 22, 2025

Morning Bell 21 January

Bell Direct
January 21, 2025

Morning Bell 20 January

Bell Direct
January 20, 2025

Weekly Wrap 17 January

Bell Direct
January 17, 2025

Morning Bell 16 January

Bell Direct
January 16, 2025

Morning Bell 15 January

Bell Direct
January 15, 2025

Morning Bell 14 January

Bell Direct
January 14, 2025

Morning Bell 13 January

Bell Direct
January 13, 2025

Weekly Wrap 10 January

Bell Direct
January 10, 2025

Morning Bell 9 January

Bell Direct
January 9, 2025

Morning Bell 8 January

Bell Direct
January 8, 2025

Morning Bell 7 January

Bell Direct
January 7, 2025